U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06898424) titled 'Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression' on March 20.
Brief Summary: This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.
Study Start Date: March 01, 2024
Study Type: INTERVENTIONAL
Condition:
Alzheimer Type Dementia
Alzheimer's Disease (AD)
Intervention:
BEHAVIORAL: Ketoflex 12/3 Diet
plant-based ketogenic diet combined with intermittent fasting (12/3)
Recruit...